COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

For most brain and spine tumors, the pathological evaluation of tumor tissue is key to planning the most effective treatment. The Brain and Spine Tumor Program includes a board-certified neuropathologist — a pathologist with special training in diagnosing abnormalities of the brain, spine and other nerve tissues.

Prism: Powerful Brain-Imaging Technology

Technology developed at the Medical College of Wisconsin and first used at Froedtert Hospital is helping make brain surgery safer. The technology is a computer system known as Prism, created by Kyron Clinical Imaging Inc. that helps physicians understand the workings of the brain like never before. 

One risk of brain surgery is the possibility of complications like paralysis or impeded speech. The new Kyron system enhances the surgical planning process by merging separate images into a single unified view. 

Prism helps physicians create surgical plans with the best chance of preserving critical brain functions. Patients at Froedtert & the Medical College of Wisconsin were the first in the world to benefit from this new imaging technology.

Permanent Section Diagnosis

After a brain or spine tumor is removed during surgery (or tumor tissue is obtained through a needle biopsy procedure), it is sent to the pathology lab. A sample of the tumor is processed, fixed in paraffin and sliced into very thin sections. The sections are then stained with chemicals that provide contrast to aid examination under a light microscope.

In general, tumor tissue samples are evaluated in terms of how different they are from normal brain or spine tissue. Key tumor characteristics include:

  • Shape and size (many cancer cells have a distinctive form)
  • Hypercellularity (tumor tissue tends to feature many cells crowded together)
  • Evidence of rapid division (certain structures identify cells that are proliferating quickly)
  • An abundance of blood vessels (tumors establish their own blood supply)
  • Necrosis (many high-grade tumors grow so quickly that they outstrip their blood supply, resulting in areas of tumor cell death)

The neuropathologist’s final diagnosis of cancer type and grade is presented at the weekly tumor board meeting of the Brain and Spine Tumor Program. During the meeting, the care team might discuss the need for additional pathological tests, including any tumor cell genetic studies that could help shape the treatment approach.

Frozen Section Analysis

During some brain surgeries, a surgeon will remove a small portion of abnormal tissue for immediate analysis. The tissue is frozen, cut into thin slices, then evaluated under a microscope. Frozen tumor sections are not as high-quality as permanent section samples, but they allow the neuropathologist to make a preliminary diagnosis while the patient is still in the operating room. Based on these initial findings, the surgeon may remove additional samples, proceed with a larger resection, modify the surgical plan or conclude the procedure.

Brain Tumor Gene Studies

Patients who have the same type of tumor often respond very differently to treatment. Researchers are finding that this can be the result of differences in the genetics of individual tumors. Tests that analyze the genetic structure of tumor cells are becoming increasingly important in neurological cancer.

The Brain and Spine Tumor Program offers the most up-to-date cytogenetic testing available. Currently, brain tumor gene testing does not determine specific drug treatments, but it can provide prognostic information that helps physicians make decisions about the timing of treatment.

Virtual Visits Are Available

Safe and convenient virtual visits by video let you get the care you need via a mobile device, tablet or computer wherever you are. We’ll gather your medical records for you and get our experts’ input so we can offer treatment options without an in-person visit. To schedule a virtual visit, call 1-866-680-0505.

Learn More

Cancer and the COVID-19 Vaccine

There is currently no data that suggests current or former cancer patients should avoid getting the COVID-19 vaccine. Cancer can weaken your immune system, so we recommend that most patients get the vaccine as soon as possible.